Every Form 4 that Aquestive Therapeutics, Inc. (AQST) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AQST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AQST filings page.
Aquestive Therapeutics, Inc. (AQST) reported that Chief Commercial Officer Sherry Korczynski exercised stock options and sold shares on September 9, 2026. She exercised 8,750 non-qualified stock options at an exercise price of $2.65 per share, converting them into 8,750 shares of common stock, and then sold 8,750 common shares at $5.22 per share. Following the option exercise, she held 26,250 stock options directly, with the exercised option series expiring on March 7, 2035. The sales were made pursuant to a previously adopted Rule 10b5-1 Trading Plan, indicating they were pre-arranged.
Aquestive Therapeutics, Inc. (AQST) reported that Chief People Officer Peter E. Boyd exercised a Common Stock Purchase Warrant on September 9, 2026 to acquire 2,293 shares of common stock at an exercise price of $0.96 per share, a cash exercise of a warrant issued in June 2022. The corresponding warrant position of 2,293 warrant rights was fully exercised, leaving no remaining warrants from this grant, and Boyd now holds 284,024 shares of Aquestive common stock directly. No Rule 10b5-1 trading plan is reported for these transactions.
Aquestive Therapeutics, Inc. (AQST) reported that President and CEO Daniel Barber exercised a Common Stock Purchase Warrant for 91,743 shares of common stock on September 8, 2026 at an exercise price of $0.96 per share for cash, increasing his direct common stock holdings to 677,317 shares and exhausting the warrant.
Aquestive Therapeutics, Inc. (AQST) reported that Chief Operating Officer Cassie Jung exercised a warrant to acquire 4,587 shares of Common Stock on September 3, 2026 by paying an exercise price of $0.96 per share, in a transaction not reported as made under a Rule 10b5-1 plan.
The related warrant, originally issued on June 8, 2022 under a Securities Purchase Agreement dated June 6, 2022, became exercisable on December 8, 2022 and expires on June 8, 2027, and now reflects 0 warrants remaining after the exercise. Following this transaction, Jung holds 206,833 shares of Common Stock directly and 2,000 shares indirectly through her spouse.
Aquestive Therapeutics, Inc. (AQST) reported that its President and CEO, Daniel Barber, sold common stock pursuant to a Rule 10b5-1 trading plan. On 2026-08-17, he sold 25,000 shares of common stock in open market or private transactions at a weighted average price of $4.2867 per share, with individual sale prices ranging from $4.24 to $4.35 per share. Following this transaction, Barber directly holds 585,574 shares of Aquestive Therapeutics common stock.
Aquestive Therapeutics, Inc. executive Sherry Korczynski, Chief Commercial Officer, reported a Form 4 transaction involving company common stock. On 2026-08-14, 2,714 shares of common stock were withheld by the issuer at $4.25 per share to satisfy her tax withholding obligation arising from the vesting of previously granted Restricted Stock Units (RSUs). After this tax-withholding disposition, she directly holds 235,689 shares of Aquestive Therapeutics common stock.
Daniel Barber, President and CEO of Aquestive Therapeutics, sold a total of 25,000 shares of common stock in open-market or private transactions on July 15–16, 2026, at prices between $4.00 and $4.04 per share, under a Rule 10b5-1 trading plan, and now directly holds 610,574 shares.
Aquestive Therapeutics director Julie Krop exercised and sold company stock under a pre-set trading plan. On June 23, 2026, she exercised options for 25,000 shares of common stock at $0.7132 per share, then sold 25,000 shares at an average price of $5.0157 in an open-market transaction.
Both the option exercise and the sale were carried out pursuant to a previously adopted Rule 10b5-1 trading plan. Following these transactions, the filing shows 0 shares of common stock held directly and no remaining listed derivative positions.
Aquestive Therapeutics President and CEO Daniel Barber reported an open-market sale of 25,000 shares of common stock. The shares were sold at a weighted average price of $4.1604 per share, within a range from $4.14 to $4.235 per share.
After this transaction, Barber directly holds 635,574 shares of Aquestive Therapeutics common stock.
Aquestive Therapeutics director Timothy E. Morris received a grant of 50,500 stock options. These options give him the right to buy 50,500 shares of common stock at an exercise price of $3.99 per share. The options expire on June 10, 2036.
All of the underlying shares vest on June 10, 2027, provided Mr. Morris remains in continuous service with the company through that date. This is a compensation-related award rather than an open-market stock purchase or sale.
Aquestive Therapeutics director Julie Krop received a compensation-related stock option grant. She was awarded options to purchase 50,500 shares of Common Stock at an exercise price of $3.99 per share, expiring on June 10, 2036.
All 50,500 underlying shares vest 100% on June 10, 2027, subject to Dr. Krop’s continuous service with Aquestive Therapeutics through that date. After this grant, she holds 50,500 stock options directly, and the filing reports no share sales or open-market purchases.
Aquestive Therapeutics director Abigail L. Jenkins received an equity award of non-qualified stock options for 50,500 shares of common stock. The options have an exercise price of $3.99 per share, expire on June 10, 2036, and represent her direct holdings of this option grant.
All 50,500 underlying shares vest on June 10, 2027, provided she remains in continuous service with the company through that date. This is a compensation-related grant, not an open-market purchase or sale, so it mainly updates her potential future ownership rather than reflecting a trading decision.
Aquestive Therapeutics director John Cochran received a grant of 50,500 stock options on Common Stock as compensation. These options have an exercise price of $3.99 per share and expire on June 10, 2036. All 50,500 underlying shares vest on June 10, 2027, if he continues serving the company through that date.
Following this filing, Cochran directly holds 99,486 shares of Common Stock, separate from the new option award. The grant increases his potential future equity exposure but involves no open-market buying or selling of shares at this time.
Aquestive Therapeutics director Gregory B. Brown reported an equity compensation award. He received a grant of stock options covering 50,500 shares of Common Stock at an exercise price of $3.99 per share.
The options vest 100% on June 10, 2027, subject to his continuous service with the company through that date. Following this report, he directly holds 75,085 shares of Common Stock and the newly granted 50,500 stock options.
Aquestive Therapeutics director Marco Taglietti received a grant of stock options covering 50,500 shares of common stock. These options have an exercise price of $3.99 per share and expire on June 10, 2036. All 50,500 underlying shares vest on June 10, 2027, if he remains in continuous service through that date.
Aquestive Therapeutics, Inc. reported a routine insider tax event involving its Chief Commercial Officer, Sherry Korczynski. On this Form 4, the company withheld 2,714 shares of common stock to cover her tax withholding obligation tied to the vesting of previously granted RSUs.
These shares were not sold on the open market; they were retained by the issuer to satisfy taxes. After this withholding, Korczynski directly holds 238,403 shares of Aquestive Therapeutics common stock, reflecting her ongoing equity stake following the RSU vesting.
Aquestive Therapeutics reported that Chief Legal Officer Thomas A. Zalewski received equity-based compensation. He was granted 100,000 shares of restricted Common Stock, which will vest in three annual installments of 25%, 25%, and 50%. He also received a Non-Qualified Stock Option for 75,000 shares of Common Stock at an exercise price of $4.135 per share, vesting on the same 25%/25%/50% schedule and expiring in 2036. After these awards, his reported holdings from this grant are 100,000 shares of Common Stock and options for 75,000 underlying shares.
Aquestive Therapeutics President and CEO Daniel Barber reported an open-market sale of 8,257 shares of Common Stock. The weighted average sale price was $4.2889 per share, with individual trades ranging from $4.17 to $4.64. After this transaction, he directly holds 660,574 shares.
Aquestive Therapeutics, Inc. executive Melina Cioffi, SVP of Regulatory Affairs, reported a routine tax-related share disposition. On the transaction date, 1,667 shares of common stock were withheld by the company at $4.17 per share to cover tax obligations from vesting RSUs. After this withholding, Cioffi directly holds 273,200 shares of common stock, indicating the event is part of equity compensation mechanics rather than an open-market sale.
Aquestive Therapeutics Corporate Secretary reports routine tax withholding transaction. On the disposition date, 135,690 shares of common stock were withheld by the company to cover Lori J. Braender’s tax withholding obligation related to vesting Restricted Stock Units. After this non-market transaction, she directly holds 231,042 shares of common stock.
Aquestive Therapeutics Chief People Officer Peter E. Boyd reported a tax-related share disposition tied to equity compensation. On the vesting of previously granted Performance Stock Units, 56,778 shares of common stock were withheld by Aquestive to cover his tax withholding obligation at $4.18 per share.
After this tax withholding event, Boyd directly holds 281,731 shares of Aquestive Therapeutics common stock. The transaction was coded as a tax-withholding disposition (code F), indicating an administrative settlement of taxes rather than an open-market trade.
Aquestive Therapeutics President and CEO Daniel Barber reported a compensation-related share adjustment. On the vesting of previously granted Performance Stock Units, the company withheld 335,922 shares of common stock at $4.18 per share to cover his tax withholding obligation. After this tax-withholding disposition, Barber directly owns 668,831 common shares, and the filing shows no remaining derivative positions.
Aquestive Therapeutics, Inc. Chief Financial Officer Ernest A. Toth Jr. reported a routine tax-related share disposition. On May 5, 2026, 92,652 shares of common stock were withheld at $4.18 per share to cover taxes on vesting Performance Stock Units. After this withholding, he continues to directly hold 283,460 shares of Aquestive common stock.
Aquestive Therapeutics, Inc. Chief Operating Officer Cassie Jung reported a compensation-related share disposition tied to tax withholding. On May 5, 2026, 72,734 shares of common stock were withheld by the company at $4.18 per share to cover her tax obligation on vesting Performance Stock Units. After this tax-withholding transaction, she directly holds 202,246 common shares, and there is an additional 2,000-share indirect holding reported in her spouse’s name. The filing does not show an open‑market sale; it reflects routine tax settlement on equity compensation.
Aquestive Therapeutics, Inc. Corporate Secretary Lori J. Braender reported a routine tax-related share disposition. On May 5, 2026, 76,147 shares of common stock were withheld at $4.18 per share to cover her tax withholding obligation tied to vesting Performance Stock Units.
These shares were retained by the company rather than sold in the open market. After this withholding, Braender directly owned 366,732 shares of Aquestive Therapeutics common stock, indicating she continues to hold a substantial equity position.
Aquestive Therapeutics, Inc. President and CEO Daniel Barber received a grant of 293,100 Performance Stock Units (PSUs) on March 7, 2025. Each PSU represents a contingent right to receive one share of common stock at no exercise price.
The PSUs measure performance from March 7, 2025 through March 7, 2028 and, if earned, will vest 100% on March 7, 2028. The award’s “Performance Price” is based on specified 30-day average Nasdaq closing prices during two measurement periods within this three-year term. The filing notes it was submitted late due to an inadvertent administrative oversight.
Boyd Peter E. reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics, Inc. reported that Chief People Officer Peter E. Boyd received a grant of 60,000 Performance Stock Units (PSUs) on March 7, 2025. Each PSU is a contingent right to receive one share of common stock if performance conditions are met.
The PSUs measure performance from March 7, 2025 through March 7, 2028 and, if earned, vest 100% on March 7, 2028. Performance is tied to specified 30-day average Nasdaq closing prices over two measurement periods. The filing notes it was submitted late due to an inadvertent administrative oversight.
Jung Cassie reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics Chief Operating Officer Cassie Jung received a grant of 60,000 Performance Stock Units (PSUs), each tied to one share of common stock. The PSUs measure performance from March 7, 2025 through March 7, 2028 and, if earned, vest 100% on March 7, 2028.
The award’s payout depends on the company’s share price over two multi-year periods, using defined 30‑day average Nasdaq closing prices. After this grant, Jung directly holds 60,000 PSUs, and there were no reported open‑market buys or sells in this filing.
TOTH A ERNEST JR reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics reported that its SVP and Chief Financial Officer, Ernest A. Toth Jr., received a grant of 82,500 Performance Stock Units (PSUs) on March 7, 2025 as equity compensation. Each PSU gives a contingent right to one share of common stock, vesting 100% on March 7, 2028 if performance conditions are met.
The PSUs measure stock performance between March 7, 2025 and March 7, 2028 using defined 30‑day average Nasdaq closing price periods. This was a direct award, not an open‑market purchase or sale. The Form 4 notes it was filed late due to an inadvertent administrative oversight.
Korczynski Sherry reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics reported that Chief Commercial Officer Sherry Korczynski received a grant of 67,500 Performance Stock Units (PSUs). Each PSU represents a contingent right to receive one share of common stock, with no cash paid by the executive at grant.
The PSUs measure performance from March 7, 2025 through March 7, 2028 and, if earned, will vest 100% on March 7, 2028. Performance is tied to a defined “Performance Price,” based on 30‑day average Nasdaq closing prices over two measurement periods, aligning the award’s value with the company’s share performance.
BRAENDER LORI J reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics, Inc. Corporate Secretary Lori J. Braender received a grant of 82,500 Performance Stock Units on March 7, 2025. Each unit represents a contingent right to one share of common stock and measures performance from March 7, 2025 through March 7, 2028.
If earned under the performance formula, the units vest 100% on March 7, 2028, with the award expiring on that date. The filing notes it was submitted late due to an inadvertent administrative oversight.
Aquestive Therapeutics Chief People Officer Peter E. Boyd reported equity awards and a mandated tax-related share sale. On March 9, he received 80,000 shares of restricted Common Stock that vest over three annual installments (25%, 25%, 50%), and a non-qualified stock option for 42,500 shares of Common Stock at $4.29 per share, expiring on March 9, 2036, with the same vesting pattern.
On March 10, 29,814 shares of Common Stock were sold at a weighted average price of $4.173 per share solely to cover tax withholding obligations tied to restricted stock unit vesting, as required by the company’s equity plans and not as discretionary trading. After these transactions, Boyd directly holds 338,509 shares of Common Stock plus the newly granted option for 42,500 shares.
Aquestive Therapeutics President and CEO Daniel Barber reported compensation-related equity activity and a mandated tax sale. On March 9, 2026, he received 262,000 shares of restricted Common Stock at no cost and 523,000 non-qualified stock options with a $4.29 exercise price, each vesting 25%, 25%, then 50% over three annual installments. On March 10, 2026, he sold 180,677 Common shares at a weighted average price of $4.173 in trades between $4.17 and $4.33 to cover tax withholding obligations from restricted stock unit vesting, as required by the company’s equity plan, rather than as discretionary trading. After the sale, he directly owned 1,004,753 Common shares and held the newly granted options for 523,000 underlying shares.
Aquestive Therapeutics Chief Legal Officer Lori J. Braender received new equity awards and executed a tax-related share sale. She was granted 80,000 shares of restricted stock, which will vest in three annual installments of 25%, 25%, and 50%. She also received 50,000 non-qualified stock options to buy common stock at $4.29 per share, vesting on the same 25%/25%/50% schedule and expiring in 2036. On March 10, 2026, she sold 40,102 shares of common stock at a weighted average price of $4.173 per share to cover tax withholding obligations from restricted stock unit vesting, a mandated “sell to cover” transaction rather than a discretionary trade. After these transactions, she directly holds 442,879 shares of common stock.
Aquestive Therapeutics SVP Melina Cioffi reported a mix of stock grants and tax-related sales. She received 100,000 shares of restricted common stock at no cost and a grant of options for 75,000 shares at a $4.29 exercise price, both vesting over three annual installments of 25%, 25%, and 50%.
On a separate date, she sold 25,311 common shares at a weighted average price of $4.173 per share to cover tax withholding tied to restricted stock unit vesting, a transaction mandated by the company’s equity plans rather than a discretionary trade. After these transactions, she directly holds 274,867 common shares.
Aquestive Therapeutics Chief Financial Officer Ernest A. Toth Jr. reported a mix of equity compensation awards and a related share sale. He received 95,000 shares of common stock as a grant and a non-qualified stock option for 70,000 shares of common stock with a $4.29 exercise price, expiring on March 9, 2036. Both the restricted stock and options vest over three annual installments of 25%, 25%, and 50%. On March 10, 2026, he sold 58,254 shares of common stock at a weighted average price of $4.173 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations from the vesting of restricted stock units and were mandated under the company’s equity incentive plan, rather than being discretionary trades. After the sale, he directly held 376,112 shares of common stock and the newly granted option for 70,000 shares.
Aquestive Therapeutics Chief Commercial Officer Sherry Korczynski reported a mix of equity awards and related share sales. She received 75,000 shares of restricted common stock and a non-qualified stock option for 42,500 shares at $4.29 per share, vesting in three annual installments of 25%, 25% and 50%. In connection with the vesting of restricted stock units, she sold 15,741 common shares at a weighted average price of $4.173 per share to cover tax withholding obligations under the company’s equity plan, which the footnotes state were mandated “sell to cover” transactions rather than discretionary trades. After these transactions, she directly holds 241,117 common shares and the newly granted option expiring in 2036.
Aquestive Therapeutics, Inc. Chief Operating Officer Cassie Jung reported a combination of equity grants and a mandated share sale. She received 80,000 shares of restricted common stock and a non-qualified stock option for 42,500 shares at an exercise price of $4.29 per share, vesting over three annual installments. To cover tax withholding from restricted stock unit vesting, she sold 45,791 shares of common stock at a weighted average price of $4.173 per share in transactions described as required "sell to cover" trades rather than discretionary sales. After these moves, she directly holds 274,980 common shares and indirectly holds 2,000 shares through her spouse, along with the newly granted option expiring on March 9, 2036.
Aquestive Therapeutics, Inc. reported that its Chief Development Officer, Matthew W. Davis, received new equity compensation. On March 9, 2026, he was granted a non-qualified stock option for 50,000 shares of common stock at an exercise price of $4.29 per share, expiring on March 9, 2036. He was also granted 50,000 shares of restricted common stock at no cash cost. The restricted stock will vest in three annual installments with 25% on the first installment, 25% on the second, and 50% on the third, and the option will vest on the same schedule. Following these grants, his direct common stock holdings reported in this filing total 100,000 shares.
Greenhawt Matthew J. reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics Chief Medical Officer Matthew J. Greenhawt received new equity awards. He was granted a non-qualified stock option for 50,000 shares of Common Stock at $4.29 per share, expiring on March 9, 2036. The option vests in three annual installments of 25%, 25%, and 50%.
He also received 75,000 shares of restricted Common Stock at no cost, vesting on the same 25%, 25%, and 50% schedule. Following these grants, he holds 75,000 shares of Common Stock directly, 50,000 option shares directly, and 2,000 shares indirectly through his spouse.
Aquestive Therapeutics (AQST) reported an insider equity award to its Chief Development Officer. On 11/10/2025, the officer acquired 50,000 shares of Common Stock at $0, described as restricted stock that vests over three annual installments (25%, 25%, 50%). The filing also shows a non-qualified stock option for 50,000 shares at an exercise price of $5.58, granted on 11/10/2025 and expiring on 11/10/2035, with the same 25/25/50 vesting schedule.
Aquestive Therapeutics (AQST) Chief Operating Officer reported transactions on 10/15/2025. The officer exercised 25,000 non-qualified stock options at a $3.1027 exercise price (code M) and sold 67,575 shares at an average price of $7.01 (code S), pursuant to a Rule 10b5-1 trading plan.
Following the transactions, the officer beneficially owned 240,771 shares directly and 2,000 shares indirectly by spouse. The reported option, granted on June 10, 2021, is fully vested and shows 0 derivative securities remaining after the exercise.
Aquestive Therapeutics (AQST) reported an insider transaction: the Chief Medical Officer sold 20,272 shares of common stock on 10/15/2025 at a weighted average price of $7.00, with individual trades ranging from $7.00 to $7.02, executed under a Rule 10b5-1 trading plan.
After the transaction, the reporting person beneficially owned 282,475 shares, held directly.
Aquestive Therapeutics (AQST) reported an insider transaction on a Form 4. An officer sold 10,000 shares of common stock at $7 on 10/15/2025, reported with transaction code S.
The filing states the sales were effected pursuant to a previously adopted Rule 10b5-1 trading plan. Following the transaction, the reporting person beneficially owns 268,323 shares, held directly. The officer’s title is SVP IT, HR, & Communications.
Daniel Barber, President and CEO and a director of Aquestive Therapeutics (AQST), reported the sale of 91,343 shares on 09/26/2025 under a previously adopted Rule 10b5-1 trading plan. The sales were executed at prices ranging from $6.00 to $6.11 per share, with a weighted average price of $6.0343. After the reported transactions, Mr. Barber beneficially owned 923,430 shares. The filer notes they will provide, upon request, details on the number of shares sold at each separate price.
Aquestive Therapeutics (AQST) insider sale: Peter E. Boyd, an officer serving as SVP IT, HR & Communications, reported a sale of 10,000 shares of the company’s common stock on 09/26/2025 at a price of $6.30 per share. After the transaction he beneficially owned 278,323 shares. The filing states the sales were effected under a previously adopted Rule 10b5-1 trading plan. The Form 4 was signed by attorney-in-fact Lori Braender on 09/29/2025.
Daniel Barber, President & CEO and director of Aquestive Therapeutics (AQST), reported a sale of common stock executed on 09/19/2025. The Form 4 shows 400 shares were disposed of at $6.00 per share under a previously adopted Rule 10b5-1 trading plan.
The filing reports that after the sale Barber beneficially owns 1,014,773 shares. The Form 4 was submitted by one reporting person and signed on behalf of Barber by an attorney-in-fact, Lori Braender, on 09/22/2025.